Nouscom, a Swiss biotech company, has raised €120 million (about $135 million) from investors to move its experimental cancer-prevention treatment into a large, final-stage clinical trial.
What the treatment is: NOUS-209 is an experimental “vaccine” designed to train the immune system to spot and destroy cells that are cancerous or on their way to becoming cancerous. It’s “off-the-shelf,” meaning it’s the same product for everyone rather than custom-made for each patient.
Who it’s for: People with Lynch Syndrome, an inherited condition that causes DNA-repair genes to malfunction. It affects an estimated two million people and raises the lifetime risk of cancer substantially (for colorectal cancer, up to about 50% versus 2% in the general population). Right now, the only options are frequent screening, such as colonoscopies, and preventive surgery, which is invasive. Screening doesn’t lower the chance of getting cancer; it just helps catch it early.
The early results: In an early-stage trial, people with Lynch Syndrome who received the vaccine stayed free of advanced precancerous growths and colorectal cancer, as checked by colonoscopy. This held for 43 people at one year and 17 at two years. Their immune systems also showed strong, lasting responses, which got stronger with yearly booster doses. The company says this looks promising compared to what would normally be expected in this population. The numbers are small, and there was no comparison group, so this is an encouraging signal rather than proof.
What happens next:
- The new money will fund a single, global trial intended to support regulatory approval. The US FDA has given the treatment “Fast Track” status, which is meant to speed up development and review.
- The latest data will be presented at a major cancer conference (ESMO) in Madrid on 25 October 2026.
- NOUS-209 is also being tested in combination with another drug in patients who already have advanced colorectal cancer.
Who invested: The round was led by M Ventures and Revelation Partners. New backers include Angelini Industries, the European Investment Bank and Neva SGR, and all existing investors took part.
Bottom line: This is a promising but still experimental approach to preventing cancer in people at very high genetic risk. The funding allows the key late-stage testing to begin, but it’s not yet an approved treatment, and the larger trial will show whether the early results hold up.
